| 1 |
中华医学会重症医学分会. 中国成人ICU镇痛和镇静治疗指南 [J]. 中华危重病急救医学, 2018, 30(6): 497-514.
|
| 2 |
Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU [J]. Crit Care Med, 2018, 46(9): e825-e873.
|
| 3 |
Orsini J,Nadkarni A,Chen J,et al. Propofol infusion syndrome: case report and literature review [J]. Am J Health Syst Pharm, 2009, 66: 908-915.
|
| 4 |
Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056: A novel ultra-short-acting Benzodiazepine [J]. Anesthesiology, 2007, 107(1): 60-66.
|
| 5 |
Jacob TC, Moss SJ, Jurd R. GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition [J]. Nat Rev Neurosci, 2008, 9(5): 331-343.
|
| 6 |
Wiltshire HR, Kilpatrick GJ, Tilbrook GS, et al. A placebo- and midazolam-controlled phase Ⅰ single ascendingdose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part Ⅱ. Population pharmacokinetic and pharmacodynamic modeling and simulation [J]. Anesth Analg, 2012, 115(2): 284-296.
|
| 7 |
Antonik LJ, Goldwater DR, Kilpatrick GJ, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part Ⅰ. safety, efficacy, and basic pharmacokinetics [J]. Anesth Analg, 2012, 115(2): 274-283.
|
| 8 |
Schüttler J, Eisenried A, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: Part I. Pharmacokinetics and Clinical Pharmacodynamics [J]. Anesthesiology, 2020, 132(4): 636-651.
|
| 9 |
Zhou Y, Hu P, Jiang J. Metabolite characterization of a novel sedative drug, remimazolam in human plasma and urine using ultra high-performance liquid chromatography coupled with synapt high-definition mass spectrometry [J]. J Pharm Biomed Anal, 2017, 137(15): 78-83.
|
| 10 |
Antonik LJ, Goldwater DR, Kilpatrick GJ, et al. A Placebo- and midazolam-controlled phase i single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part Ⅰ. safety, efficacy, and basic pharmacokinetics [J]. Anesth Analg, 2012, 115(2): 274-283.
|
| 11 |
Wiltshire HR, Kilpatrick GJ, Tilbrook GS, et al. A placebo- and midazolam-controlled phase ⅰ single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (cns 7056): part ⅱ. population pharmacokinetic and pharmacodynamic modeling and simulation [J]. Anesth Analg, 2012, 115(2): 284-296.
|
| 12 |
Worthington MT, Antonik LJ, Goldwater DR, et al. A phase ⅠbA, dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy [J]. Anesth Analg, 2013, 117(5): 1093-1100.
|
| 13 |
Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056: a novel ultra-short-acting benzodiazepine [J]. Anesthesiology, 2007, 107(1): 60-66.
|
| 14 |
Bevans T, Deering-Rice C, Stockmann C, et al. Inhaled remimazolam potentiates inhaled remifentanil in rodents [J]. Anesth Analg, 2017, 124(5): 1484-1490.
|
| 15 |
Upton R, Martinez A, Grant C. A dose escalation study in sheep of the effects of the benzodiazepine CNS 7056 on sedation, the EEG and the respiratory and cardiovascular systems [J]. Br J Pharmacol, 2008, 155(1): 52-61.
|
| 16 |
Pambianco DJ, Borkett KM, Riff DS, et al. A phase Ⅱb study comparing the safety and efficacy of Remimazolam and Midazolam in patients undergoing colonoscopy [J]. Gastrointest Endosc, 2016, 83(5): 984-992.
|
| 17 |
Probst S, Bevilacqua C, Eibel S, et al. Difference in vasopressor use and usage patterns in patients undergoing cardiac surgery with remimazolam versus propofol/sevoflurane for general anesthesia [J]. Amer Soc Anesthesiol.[2015-10-27].
|
| 18 |
Freyer N, Knöspel F, Damm G, et al. Metabolism of remimazolam in primary human hepatocytes during continuous long-term infusion in a 3-D bioreactor system [J]. Drug Des Devel Ther, 2019, 13(2): 1033-1047.
|
| 19 |
Tsai HC, Lin YC, Ko CL, et al. Propofol versus midazolam for upper gastrointestinal endoscopy in cirrhotic patients: a meta-analysis of randomized controlled trials [J]. PLoS One, 2015, 10(2) : e0117585.
|
| 20 |
Pastis NJ, Yarmus LB, Schippers F. Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy [J]. Chest, 2019, 155(1): 137-146.
|
| 21 |
Rogers WK, McDowell TS. Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures [J]. IDrugs, 2010, 13(12): 929-937.
|
| 22 |
Rex DK, Bhandari R, Desta T, et al. A phase Ⅲ study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy [J]. Gastrointest Endosc, 2018, 88(3): 427-437.
|
| 23 |
Doi M, Morita K, Shiraishi Y, et al. Remimazolam dose finding studies for anesthetic/sedative in the indication general anesthesia in Japanese voluneers/patients.Poster session presented at: the ANESTHESIOLOGY 2015 annual meeting[J];2015, Oct 24-28; San Diego, CA.
|
| 24 |
Sato S, Doi M, Morita K, et al. Remimazolam a new ultra-short acting anesthetic shows similar efficacy and superior hemodynamic stability vs propofol in general surgery patients with TIVA: Results of a randomized, non-inferiority, phase Ⅱb/Ⅲ trial [J]. Amer Soc Anesthesiol.[2015-10-28].
|